HighPoint Advisor Group LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 2.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,591 shares of the company’s stock after selling 1,583 shares during the period. Johnson & Johnson makes up approximately 2.0% of HighPoint Advisor Group LLC’s investment portfolio, making the stock its 7th biggest position. HighPoint Advisor Group LLC’s holdings in Johnson & Johnson were worth $7,269,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Financial Gravity Wealth Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $105,000. Stelac Advisory Services LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $108,000. Princeton Capital Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $141,000. Smart Portfolios LLC purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $150,000. Finally, Signition LP purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $204,000. Institutional investors own 66.80% of the company’s stock.
JNJ has been the subject of several recent analyst reports. ValuEngine lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price target for the company. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Finally, Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $142.87.
In related news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
Shares of NYSE:JNJ opened at $139.49 on Friday. The company has a market capitalization of $373.89 billion, a P/E ratio of 19.11, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04. The company had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. Johnson & Johnson’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.83 earnings per share. sell-side analysts predict that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were paid a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date of this dividend was Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Asset Allocation and Your Retirement
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.